← Back to Search

Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS) for Sarcoma (HopES Trial)

Phase 2
Waitlist Available
Led By Sant P Chawla, MD
Research Sponsored by Sarcoma Oncology Research Center, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Non-resected, locally advanced or metastatic sarcoma (including Ewing's sarcoma) for which there is no standard of care treatment and no curative other option (for salvage treatment cohort)
Any number of prior treatments for salvage cohort
Timeline
Screening 3 weeks
Treatment Varies
Follow Up every 3 months for up to 2 years
Awards & highlights

HopES Trial Summary

This trial is testing a new cancer treatment on people who have either not responded to other treatments or have relapsed.

Eligible Conditions
  • Sarcoma
  • Ewing Sarcoma

HopES Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You have a type of cancer called sarcoma, which is advanced and cannot be removed through surgery. There is no standard treatment available for your condition, and there are no other options for a cure.
Select...
You have received any number of treatments before joining the study.

HopES Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~every 3 months for up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and every 3 months for up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall Response Rate
Therapeutic procedure
Stable Disease for at Least 3 Months
Secondary outcome measures
Clinical Benefit Rate
Duration of Response
Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v5
+1 more

HopES Trial Design

2Treatment groups
Experimental Treatment
Group I: Salvage Treatment: SarcomaExperimental Treatment1 Intervention
Combination metyrosine-derivative, low-dose methoxasalen, phenytoin and sirolimus
Group II: Maintenance Treatment: Ewing's SarcomaExperimental Treatment1 Intervention
Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus

Find a Location

Who is running the clinical trial?

Joseph Ahmed FoundationUNKNOWN
Sarcoma Oncology Research Center, LLCLead Sponsor
7 Previous Clinical Trials
535 Total Patients Enrolled
6 Trials studying Sarcoma
455 Patients Enrolled for Sarcoma
Tyme, IncIndustry Sponsor
4 Previous Clinical Trials
166 Total Patients Enrolled

Media Library

Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS) Clinical Trial Eligibility Overview. Trial Name: NCT03778996 — Phase 2
Sarcoma Research Study Groups: Maintenance Treatment: Ewing's Sarcoma, Salvage Treatment: Sarcoma
Sarcoma Clinical Trial 2023: Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS) Highlights & Side Effects. Trial Name: NCT03778996 — Phase 2
Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03778996 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does MPS stand for and what are doctors using it to treat?

"MPS, which is a combination of metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus, can help patients with epilepticus, tonic-clonic disorders, convulsive disorders, and pheochromocytomas."

Answered by AI

Are there other trials that have used this combination of drugs before?

"At the moment, a total of 136 studies are being conducted that involve Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS). Of these ongoing trials, 15 are in Phase 3. Many of the research facilities for this treatment are based Cincinnati, Ohio; however, there are 1092 locations running these experiments globally."

Answered by AI

How many individuals are being considered for this research project?

"Indeed, the clinical trial is currently ongoing and has been since 1/3/2020 according to information on clinicaltrials.gov. The study will take place at a single site and enroll 24 patients in total."

Answered by AI

Are researchers looking for more participants at this time?

"Yes, as the clinicaltrials.gov website reflects, this study is still recruiting participants. The trial was originally advertised on January 3rd 2020 and received its last update on May 4th 2022."

Answered by AI

What is the MPS drug cocktail's official standing with the FDA?

"Given that this is a phase 2 trial, meaning that while there are data supporting safety, there are none for efficacy, Power rates the combination of Metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS) as being safe to use."

Answered by AI

What goals does this trial hope to achieve?

"The key metric that will be monitored every 3 months for 2 years is 'Stable Disease for at Least 3 Months'. Other important measures of success include the 'Clinical Benefit Rate', defined as CR+PR+SD, which will use RECIST 1.1 guidelines. Additionally, researchers will track the Overall Survival rate from date of enrollment to date of death and also document any Treatment-Emergent Adverse Events using CTCAE v5 definition: 'Adverse events will be assessed at each visit and at unscheduled visits as clinically indicated.'"

Answered by AI
~6 spots leftby Mar 2025